An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis

Am J Gastroenterol. 2008 Apr;103(4):1045; author reply 1045-6. doi: 10.1111/j.1572-0241.2007.01772_5.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Bile Duct Neoplasms / blood
  • Bile Duct Neoplasms / genetics*
  • Bile Ducts, Intrahepatic*
  • Biomarkers / blood
  • Chi-Square Distribution
  • Cholangiocarcinoma / blood
  • Cholangiocarcinoma / genetics*
  • Cholangitis, Sclerosing / blood
  • Cholangitis, Sclerosing / genetics*
  • Genotype
  • Humans
  • Interleukin-6 / blood
  • Interleukin-6 / genetics*
  • Polymorphism, Single Nucleotide*
  • Risk Factors

Substances

  • Biomarkers
  • Interleukin-6